Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
Status:
Completed
Trial end date:
2020-08-13
Target enrollment:
Participant gender:
Summary
In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with
livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be
given to the study subjects shortly after transplant to protect them from developing the
problems HCV can cause to the liver.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Antiviral Agents Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir